Filing Details
- Accession Number:
- 0001209191-21-039810
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-06-11 16:10:17
- Reporting Period:
- 2021-06-10
- Accepted Time:
- 2021-06-11 16:10:17
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1549595 | Nurix Therapeutics Inc. | NRIX | Pharmaceutical Preparations (2834) | 270838048 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1817226 | Pierre Beaurang | C/O Nurix Therapeutics, Inc. 1700 Owens Street, Suite 205 San Francisco CA 94158 | Chief Business Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-06-10 | 7,500 | $1.11 | 11,830 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-06-10 | 6,000 | $29.15 | 5,830 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-06-10 | 1,100 | $30.01 | 4,730 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-06-10 | 400 | $30.90 | 4,330 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Employee Stock Option (right to buy) | Disposition | 2021-06-10 | 7,500 | $0.00 | 7,500 | $1.11 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
21,562 | 2027-02-01 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 116,666 | Indirect | By Trust |
Footnotes
- This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
- Represents the weighted average sale price. The lowest price at which shares were sold was $28.64 and the highest price at which shares were sold was $29.62. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.
- Represents the weighted average sale price. The lowest price at which shares were sold was $29.67 and the highest price at which shares were sold was $30.57.
- Represents the weighted average sale price. The lowest price at which shares were sold was $30.765 and the highest price at which shares were sold was $30.95.
- The Reporting Person is a trustee of the Beaurang-Sligh Family Trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
- The option is fully vested.